Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to compare the performance of the NOWDx Syphilis Test to a currently marketed device. The intent is to show the rapid test device is comparable to the currently marketed device. The NOWDx Syphilis Test is intended for qualitatively detecting the presence or absence of human antibodies to syphilis in human whole blood to aid in the diagnosis of infection caused by Treponema pallidum.
The objective of this study is to establish the performance characteristics of the NOWDx Syphilis Test based on comparison to the BioRad Bioplex 2200 series Syphilis Total (IgG/IgM), Wampole Impact RPR Test Kit, and to the Serodia Treponema pallidum particle agglutination assay (TP-PA).
The external clinical study along with in-house analytical studies will demonstrate the efficacy of the NOWDx Syphilis Test as an aid in the diagnosis of syphilis infection for at home testing and point of care testing sites. Participants will self test and be tested by Clinical Laboratory Improvement Amendments (CLIA) Waived operators with the NOWDx Syphilis Test at independent sites in WA, AZ, and NV. Two sample types will be tested with the NOWDx Syphilis Test for each participant: fingerstick whole blood and venous whole blood. Sera from each participant will be tested at an independent reference laboratory.
The NOWDx Syphilis Test will be evaluated in diverse populations of sexually active persons who self-select for syphilis testing and expectant mothers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sexually active persons who self-select for syphilis testing | Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years |
| |
| Expectant mothers | Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years |
| |
| Lay users | Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diagnostic Test: NOWDx Syphilis Test | Device | For this observational trial, the Intervention of interest is the NOWDx Syphilis Test. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Compare serological status to comparator method | The comparator method used in this study is an algorithm comprised of results from three different commercially available syphilis assays: an FDA-cleared treponemal immunoassay, an FDA-cleared non-treponemal assay (RPR assay) and a second treponemal assay (TP-PA). | through study completion, an average of 6 months |
| Evaluate test reproducibility by lay users | Test lay user reproducibility using prepared samples for % agreement with expected results. | through study completion, an average of 6 months |
Not provided
Not provided
Sexually active persons who self-select for syphilis testing
n=840 participants; ~280 per study site
Inclusion criteria:
- sexually active persons 18-64 years old
Exclusion criteria:
Expectant mothers
n=222 participants; ~74 per study site
Inclusion criteria:
- expectant mothers ≥18 years old
Exclusion criteria:
Lay users
n=48 participants; ~16 per study site
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Residents of the U.S. who elect to participate in the study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sharon Rabine, MS | NOW Diagnostics, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AMR Tempe | Tempe | Arizona | 85281 | United States | ||
| Matrix Clinical Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013587 | Syphilis |
| D014211 | Treponemal Infections |
| ID | Term |
|---|---|
| D013145 | Spirochaetales Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
Not provided
Not provided
Not provided
| Los Angeles |
| California |
| 90057 |
| United States |
| Segal Trials | North Miami | Florida | 33161 | United States |
| AMR Las Vegas | Las Vegas | Nevada | 89119 | United States |
| People Care Institute | West Orange | New Jersey | 07052 | United States |
| Multicare Rockwood | Cheney | Washington | 99004 | United States |
| D007239 | Infections |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |